| Course | HIM 310 Clinical Data Classification |
|---|---|
| Topic | Topic 8 |
| Paper type | Classification choice defense |
| Length | About 780 words, 2 pages |
| Format | Memo with APA 7 references |
| School | Grand Canyon University (GCU) |
| Program | BS in Health Information Management |
| Updated | September 2026 |
Free sample paper for HIM 310 Topic 8
Memorandum
To: Data Governance Committee, Mesquite Valley Medical Center
From: [Author Name], Health Data Analyst, Health Information Management
Date: [Date]
Re: Data source for the lung cancer histology trend request
The Question
The cancer committee has asked whether adenocarcinoma is becoming a larger share of the lung cancers diagnosed or first treated at Mesquite Valley over the last ten years, compared with squamous cell and small cell carcinoma. The question turns on histology, the microscopic type of the tumor, not only on its site. Two sources could be used: diagnosis codes on hospital claims, which the finance department can pull in a day, and the hospital's cancer registry, which takes longer. I recommend the registry, and this memo explains why the faster source cannot answer the question. The finance department's offer is generous, and claims data answer many of the committee's other questions well, such as how many lung cancer patients were admitted or what their care cost. This request is different in kind, and the choice of source decides whether the answer can be right at all.
What Each Classification Records
Table 1
How Each Classification Represents a Lung Cancer
| Feature | ICD-10-CM on claims | ICD-O-3 in the cancer registry |
|---|---|---|
| Organizing principle | Chiefly site and behavior of the neoplasm | Two separate axes: topography (site) and morphology (histology and behavior) |
| Lung adenocarcinoma versus squamous cell carcinoma | Same code, determined by site and lobe | Different morphology codes on the same topography |
| Where histology is captured | Only for some cancers, such as melanoma, lymphoma and neuroendocrine tumors | For every reportable cancer |
| Unit counted | Encounters and claims | Each primary tumor, once |
| Recorded by | Coders, from encounter documentation | Certified registrars, from pathology and full record review |
The difference is structural. ICD-10-CM classifies malignant neoplasms of the lung by site, down to the lobe and side, but a code for a malignant neoplasm of the left upper lobe is the same whether the tumor is an adenocarcinoma or a squamous cell carcinoma (Centers for Medicare & Medicaid Services & National Center for Health Statistics, 2025). ICD-O-3 was designed for cancer registries and records the site and the histology on separate axes, with a morphology code that carries the cell type and a behavior digit identifying a malignant primary tumor (Fritz et al., 2000). Only the second can separate the cell types the committee is asking about.
Why Claims Would Mislead Even for Site
Claims data have a second problem that would matter even if histology were not the issue. They count encounters, and a patient with lung cancer generates dozens of claims over a course of treatment. Turning claims into a count of new cancers requires an algorithm to find the first diagnosis, which misclassifies patients diagnosed elsewhere and treated here, and patients whose earlier encounters carried a history code. The registry counts each primary tumor once, abstracted by a registrar who reads the pathology report, and it distinguishes cases diagnosed or first treated here from those seen only for later care. Programs accredited by the Commission on Cancer must meet registry data quality standards (American College of Surgeons, 2020), which gives the committee a known level of accuracy.
The Costs of Choosing the Registry
The registry is not free of drawbacks, and the committee should approve it knowing them. It lags: cases are abstracted months after diagnosis, so the most recent year will be incomplete when the analysis is run, and I propose reporting it separately. Histology classification itself changes over time as pathology practice and coding rules are updated, and registries in the United States moved to an updated version of ICD-O-3 for recent diagnosis years, so the analysis will group morphology codes into broad histologic types, adenocarcinoma, squamous cell, small cell and other, that are stable across versions. And Mesquite Valley's registry covers only analytic cases, those diagnosed or first treated here, so a shift in which patients choose Mesquite Valley for treatment could look like a shift in histology.
Why the Answer Is Worth the Wait
The question matters because national data show the histologic types moving in different directions. Meza et al. (2015), analyzing national registry data, found that squamous, large cell and small cell carcinoma rates had been decreasing since the mid-1980s, while adenocarcinoma rates remained relatively constant in men and increased in women. If Mesquite Valley's pattern follows the national one, the cancer committee may need to plan for more targeted testing, since treatment decisions for adenocarcinoma increasingly depend on molecular testing of the tumor. A claims-based answer could not show this, and a wrong answer delivered quickly would be worse than a right one delivered in six weeks.
I ask the committee to approve the registry as the data source, with broad histology groupings, the latest year reported separately and a note on the analytic case limitation in every report produced from it.
References
American College of Surgeons. (2020). Optimal resources for cancer care: 2020 standards. Commission on Cancer.
Centers for Medicare & Medicaid Services & National Center for Health Statistics. (2025). ICD-10-CM official guidelines for coding and reporting FY 2025.
Fritz, A., Percy, C., Jack, A., Shanmugaratnam, K., Sobin, L., Parkin, D. M., & Whelan, S. (Eds.). (2000). International classification of diseases for oncology (3rd ed.). World Health Organization.
Meza, R., Meernik, C., Jeon, J., & Cote, M. L. (2015). Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. PLOS ONE, 10(3), Article e0121323. https://doi.org/10.1371/journal.pone.0121323
HIM 310 Topic 8 instructions, in plain terms
The final topic of HIM-310 asks students to recommend and defend a classification for a specific analytic purpose. Weak defenses describe both options and decline to choose, or choose the more familiar system without testing it against the question. The assignment rewards defenses written for a decision-making audience that state the question first, show why its answer depends on a particular kind of detail and demonstrate from each classification's structure which one can hold it. Students should address the drawbacks of the chosen option honestly, explain how they will be managed and connect the choice to why the question matters.
Inside the HIM 310 Topic 8 example
The finished defense is written for a data committee that has to approve the choice. It states the question first, whether particular histologic types of cancer are becoming more common among the program's patients, and shows why the answer depends on histology rather than on site alone. It then sets the two options side by side. Diagnosis codes on claims are organized chiefly by site and behavior and capture histology only for some cancers, while ICD-O-3, used in cancer registries, records topography and morphology on separate axes. The defense grants what the claims option does well, speed and coverage of every encounter, and prices what choosing the registry costs in abstraction effort and reporting delay. It closes by limiting the choice to this question and naming the operational reports that should stay on claims data.
HIM 310 Topic 8 rubric: what Excellent looks like
GCU's rubric for the classification defense rewards a choice grounded in structure. Excellent defenses show exactly what each classification records, such as site only versus site and histology on separate axes. Credit goes to identifying secondary problems with the rejected source, such as counting encounters instead of cases. Marks also reward candor about where the chosen source falls short, including lag, coding version changes and coverage, with a plan for each. The highest level explains why a correct answer is worth its cost and makes a specific request the committee can approve.
HIM 310 Topic 8 help before you submit
Defenses lose most of their marks by arguing for a system rather than for a choice. Praising ICD-O-3, or SNOMED CT, or any other system in general terms leaves the committee with no question the choice answers. Papers that dismiss the rejected option without crediting what it does well read as advocacy, and a reviewer who knows claims data will stop trusting the rest. Requirements that are never stated make the comparison impossible to check. Leaving out cost, especially the human effort of abstraction and the delay it introduces, presents a choice with no price. The last frequent gap is scope, since a defense that never limits itself to the stated question implies the chosen system should replace the other everywhere.
Get an HIM-310 Topic 8 example written to your instructions
Send the HIM-310 Topic 8 instructions and the rubric posted in your classroom, with the use, setting or systems your assignment specifies. We write a custom example to those criteria, with the question and audience stated, the requirement derived, the rejected option credited, the cost counted and the choice confined to its purpose, in 24 to 48 hours. The first one costs nothing.
More HIM 310 papers and BS in Health Information Management samples
- HIM 310 Topic 1: Code Set Purpose Comparison
- HIM 310 Topic 2: Diagnosis Hierarchy Analysis
- HIM 310 Topic 3: Procedural Logic Comparison
- HIM 310 Topic 4: Terminology Versus Classification Paper
- HIM 310 Topic 5: Granularity Trade Off Discussion
- HIM 310 Topic 6: Mapping Loss Analysis
- HIM 310 Topic 7: Fit for Purpose Evaluation
- HIM 350 Topic 8: Diagnosis Coding Audit Defense
- HIM 200 Topic 8: Plain Language Records Policy
- HIM 355 Topic 8: Procedure Code Audit Rebuttal
- HIM 490 Topic 8: Capstone Panel Defense
HIM 310 Topic 8 questions, answered
Why a cancer example rather than a common condition?
Because it shows the course's central idea with unusual clarity. A cancer program already keeps two classifications of the same disease, one serving billing and one serving registry analysis, so the question of which to use is a plausible committee decision rather than a thought experiment. If your instructions name a different use, the example is written for that use, with the same sequence of question, requirement, options, cost and scope.
Does the defense have to reject one option completely?
No, and the stronger papers seldom do. The choice applies to a stated question, so the rejected option can remain the right source for other questions. The example confines its decision to the tumor type trend and names the reports that should stay on claims data, which shows the committee the writer understands both systems rather than preferring one out of habit.
How does registry abstraction differ from coding?
Registry abstractors read the record, including pathology reports, and record a defined set of data items about each cancer case, of which topography and morphology are only two. The work follows registry standards rather than claims rules and is done for analysis, not payment. That difference in purpose explains both the richer detail and the delay, and the defense counts both when pricing the choice.
Where can I find a free HIM 310 Topic 8 sample paper?
This page holds the full defense, with the question, what each classification records, why claims mislead, the costs of the registry and why the answer is worth the wait. Tell us your analytic question for a free worked defense.
Why can't claims separate adenocarcinoma in HIM 310 Topic 8?
ICD-10-CM classifies lung cancer by site and lobe, so an adenocarcinoma and a squamous cell carcinoma of the same lobe share one code. ICD-O-3 records histology on a separate morphology axis.